Effectiveness in switching from antipsychotic polypharmacy to monotherapy in patients with schizophrenia: A case series

Hiroyuki Kamei; Hanae Yamada; Masakazu Hatano; Manako Hanya; Shigeki Yamada; Nakao Iwata

doi:10.9758/CPN.2020.18.1.159

Effectiveness in switching from antipsychotic polypharmacy to monotherapy in patients with schizophrenia: A case series

Hiroyuki Kamei, Hanae Yamada, Masakazu Hatano, Manako Hanya, Shigeki Yamada, Nakao Iwata

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.

Original language	English
Pages (from-to)	159-163
Number of pages	5
Journal	Clinical Psychopharmacology and Neuroscience
Volume	18
Issue number	1
DOIs	https://doi.org/10.9758/CPN.2020.18.1.159
Publication status	Published - 2020

All Science Journal Classification (ASJC) codes

Psychiatry and Mental health
Behavioral Neuroscience
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.9758/CPN.2020.18.1.159

Cite this

@article{137be43029bc40099b12183669e6e675,

title = "Effectiveness in switching from antipsychotic polypharmacy to monotherapy in patients with schizophrenia: A case series",

abstract = "In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.",

author = "Hiroyuki Kamei and Hanae Yamada and Masakazu Hatano and Manako Hanya and Shigeki Yamada and Nakao Iwata",

note = "Publisher Copyright: Copyright {\textcopyright} 2020, Korean College of Neuropsychopharmacology",

year = "2020",

doi = "10.9758/CPN.2020.18.1.159",

language = "English",

volume = "18",

pages = "159--163",

journal = "Clinical Psychopharmacology and Neuroscience",

issn = "1738-1088",

publisher = "Korean College of Neuropsychopharmacology",

number = "1",

}

TY - JOUR

T1 - Effectiveness in switching from antipsychotic polypharmacy to monotherapy in patients with schizophrenia

T2 - A case series

AU - Kamei, Hiroyuki

AU - Yamada, Hanae

AU - Hatano, Masakazu

AU - Hanya, Manako

AU - Yamada, Shigeki

AU - Iwata, Nakao

PY - 2020

Y1 - 2020

N2 - In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.

AB - In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=85087991007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087991007&partnerID=8YFLogxK

U2 - 10.9758/CPN.2020.18.1.159

DO - 10.9758/CPN.2020.18.1.159

M3 - Article

AN - SCOPUS:85087991007

SN - 1738-1088

VL - 18

SP - 159

EP - 163

JO - Clinical Psychopharmacology and Neuroscience

JF - Clinical Psychopharmacology and Neuroscience

IS - 1

ER -

Effectiveness in switching from antipsychotic polypharmacy to monotherapy in patients with schizophrenia: A case series

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this